Get started
Work

102P Sustained response and long-term therapeutic benefits beyond treatment cessation in NSCLC relapsed-patients treated with ateganosine and ICI in the THIO-101 trial

Year: 2026
Type: article
Abstract: Despite advancements in first-line treatments, long-term survival for advanced non-small cell lung cancer (NSCLC) remains suboptimal, with only 28% of patients surviving beyond five years. Treatment options for immune checkpoint inhibitor (ICI)-resistant patients are limited. Ateganosine (THIO, 6-thio-dG), a telomere-targeting agent, modifies telomeres in cancer cells, including circulating tumor cells (CTCs), confirming its mechanism of action and demonstrating efficacy independent of PD-L1 expression.
Source: ESMO Open
DOI: 10.1016/j.esmoop.2026.106409
Authors: T. Jankowski, M. Kowal-Rosinska, T. Csoszi, T. Nagy, V. Muller, R. Ramlau, S. Sótér, M. Kotlarski, C. Volovat, F. Amurariti, R.D. Bobora, D-E. Sirbu, I. Mender, M.R. Girotti, M. Vidotto Mitsunaga, O. Tudos, M. Failor, V. Vitoc, S. Gryaznov, V. Zaporojan
Institutions: Medical University of Lublin, Semmelweis University, National Institute of Oncology, Poznan University of Medical Sciences, Országos Korányi Tbc és Pulmonológiai Intézet, Spitalul Clinic Judeţean de Urgenţă "Pius Brînzeu" Timişoara, Universidad Argentina de la Empresa
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,910
OpenAlex ID: W7138393317
FWCI:
Cites:
Cited by:
Related to: